Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

Gilead hepatitis drug will earn $4 bn in 2014 alone

05.03.2014 / BioSpectrum

Gilead‘s hepatitis C drug, Sovaldi, which was approved in December, is among the first of a new generation of treatments that can cure the disease faster and more reliably than previous drugs.
According to Bloomberg, the drug costs $84,000 for a 12-week course of treatment and is expected to produce $4.2 billion in revenue during 2014 and $8.1 billion in 2015.
 

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: